Supplementary Table S1. Comparison of the previously published and current cohorts

Characteristic	Previously published cohort [11]	Current cohort
Sample size	147	160
Patient overlap	147 patients included in the current cohort	147 patients from previous cohort plus 13 additional eligible patients
Population	Adults with relapsed/refractory CLL treated with venetoclax-based therapy	Adults with relapsed/refractory CLL treated with venetoclax-based therapy
Primary focus	Overall real-world effectiveness and safety of venetoclax-based therapy	Comparative outcomes according to prior ibrutinib exposure
Comparison by prior ibrutinib exposure	Not the primary research question	Prior ibrutinib (n = 68) versus no prior ibrutinib (n = 92)
Outcome focus	Overall response, survival, and adverse events	Exposure-group comparisons of response, OS, PFS, safety, and adjusted survival associations
Follow-up extension	Earlier publication	Not an extension of follow-up; distinct within-cohort research question

The current analysis includes all patients in the previous cohort, with 13 additional eligible patients from the same study period. It addresses a distinct research question rather than an extension of follow-up. Reference [11] denotes the previously published cohort as cited in the main manuscript.